Starting August 1, 2024, Quickarrays Inc. will be taking over Pantomics Inc. to
provide all products and services. Please visit Quickarrays Inc. for more information.
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
Hermatopathology
OVC1021
Ovary cancer tissue array, 102 cases of normal/benign (5 cases) and cancer (97 cases) tissues with grading and TNM staging data.
Specification
Data Sheet
TNM Grading
Downloads
Price
Size
Availability
$289
1 slide
In-Stock
A | |
B | |
C | |
D | |
E | |
F | |
G | |
H | |
TNM Classification: Ovary carcinoma
T- Primary tumor
TX - Primary tumor cannot be assessed
TO - No evidence of primary tumor
T1 - Tumor limited to the ovaries
T1a - Tumor limited to one ovary; capsule intact, no tumor invasion on ovarian surface; no malignant cells in ascites or peritoneal washings
T1b - Tumor limited to both ovaries; capsule intact, no tumor invasion on ovarian surface; no malignant cells in ascites or peritoneal washings
T1c - Tumor limited to one or both ovaries with any or the following features; capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washing
T2 - Tumor involves one or both ovaries with pelvic extension
T2a - Extension and/or implants on uterus and/or tube(s); no malignant cells in ascites or peritoneal washings
T2b - Extension to other pelvic tissue; no malignant cells in ascites or peritoneal washings
T2c - Pelvic extension (T2a or T2b) with malignant cells in ascites or peritoneal washings
T3 and/or N1 - Tumor involves both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis and/or regional lymph node metastasis
T3a - Microscopic peritoneal metastasis beyond pelvis
T3b - Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension
T3c and/or N1 - Peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis
N - Regional lymph nodes
NX - Regional lymph nodes cannot be assessed
NO - No regional lymph node metastasis
N1 - Regional lymph node metastasis
M - Distant metastasis
MX - Distant metastasis cannot be assessed
MO - No distant metastasis
M1 - Distant metastasis (exclude peritoneal metastasis)
Human
102
102
1.5mm
4um
8
13
Paraffin
Notes:
All tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. They all have a guaranteed six month shelf-life at 4C from the date of shipment. Additional cores not listed are orientation markers and have no data. There maybe <5% core loss per slide but the core retention rate should be >90%.
Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength. Please check our TNM guide as a reference. For IHC related information on products that provide them, please contact us at info@pantomics.com for the most up-to-date information.
For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in ovary cancers.
ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | GRADE | STAGE (TNM) |
|---|---|---|---|---|---|---|---|
A01 | F | 37 | Ovary | Normal | |||
A02 | F | 31 | Ovary | Normal | |||
A03 | F | 50 | Ovary | Serous cystadenoma | |||
A04 | F | 22 | Ovary | Mucinous cystadenoma | |||
A05 | F | 37 | Ovary | Borderline mixed cystadenoma | |||
A06 | F | 48 | Ovary | Clear cell carcinoma | T1N0M0 | ||
A07 | F | 26 | Ovary | Serous cystadenocarcinoma | I | T1N0M0 | |
A08 | F | 20 | Ovary | Serous cystadenocarcinoma | I~II | T1N0M0 | |
A09 | F | 34 | Ovary | Serous cystadenocarcinoma | I | T2N0M0 | |
A10 | F | 29 | Ovary | Serous cystadenocarcinoma | I | T1N0M0 | |
A11 | F | 57 | Ovary | Mucinous cystadenocarcinoma | I | T1N0M0 | |
A12 | F | 41 | Ovary | Serous cystadenocarcinoma | I | T1N0M0 | |
A13 | F | 30 | Ovary | Serous cystadenocarcinoma | I | T1N0M0 | |
B01 | F | 27 | Ovary | Serous cystadenocarcinoma | I | T1N0M0 | |
B02 | F | 31 | Ovary | Serous cystadenocarcinoma | I | T1N0M0 | |
B03 | F | 50 | Ovary | Serous cystadenocarcinoma | I | T1N0M0 | |
B04 | F | 26 | Ovary | Serous cystadenocarcinoma | I | T1N0M0 | |
B05 | F | 29 | Ovary | Serous cystadenocarcinoma | I | T3N0M0 | |
B06 | F | 61 | Ovary | Serous cystadenocarcinoma | I~II | T3N0M1 | |
B07 | F | 56 | Ovary | Serous cystadenocarcinoma | I~II | T3N0M1 | |
B08 | F | 54 | Ovary | Mucinous cystadenocarcinoma | I~II | T1N0M0 | |
B09 | F | 42 | Ovary | Mucinous cystadenocarcinoma | I~II | T1N0M0 | |
B10 | F | 35 | Ovary | Serous cystadenocarcinoma | I~II | T3N0M1 | |
B11 | F | 56 | Ovary | Serous cystadenocarcinoma | II~III | T3N0M1 | |
B12 | F | 48 | Ovary | Serous cystadenocarcinoma | II | T1N0M0 | |
B13 | F | 54 | Ovary | Serous cystadenocarcinoma | II | T1N0M0 | |
C01 | F | 55 | Ovary | Serous cystadenocarcinoma | II | T3N0M1 | |
C02 | F | 72 | Ovary | Serous cystadenocarcinoma | II | T1N0M0 | |
C03 | F | 57 | Ovary | Serous cystadenocarcinoma | II | T2N0M0 | |
C04 | F | 51 | Ovary | Serous cystadenocarcinoma | II | T2N0M0 | |
C05 | F | 51 | Ovary | Serous cystadenocarcinoma | II | T1N0M0 | |
C06 | F | 75 | Ovary | Serous cystadenocarcinoma | II | T2N0M0 | |
C07 | F | 65 | Ovary | Endometrioid adenocarcinoma | II~III | T1N0M0 | |
C08 | F | 42 | Ovary | Serous cystadenocarcinoma | II~III | T2N0M0 | |
C09 | F | 42 | Ovary | Serous cystadenocarcinoma | II~III | T3N0M1 | |
C10 | F | 54 | Ovary | Serous cystadenocarcinoma | II~III | T3N1M1 | |
C11 | F | 51 | Ovary | Serous cystadenocarcinoma | II~III | T3N0M1 | |
C12 | F | 51 | Ovary | Serous cystadenocarcinoma | III | T3N1M1 | |
C13 | F | 45 | Ovary | Serous cystadenocarcinoma | III | T2N0M0 | |
D01 | F | 50 | Ovary | Endometrioid adenocarcinoma | III | T1N0M0 | |
D02 | F | 39 | Ovary | Endometrioid adenocarcinoma | III | T2N0M0 | |
D03 | F | 74 | Ovary | Serous cystadenocarcinoma | III | T1N0M0 | |
D04 | F | 56 | Ovary | Serous cystadenocarcinoma | III | T3N0M1 | |
D05 | F | 54 | Ovary | Serous cystadenocarcinoma | III | T3N0M1 | |
D06 | F | 60 | Ovary | Serous cystadenocarcinoma | III | T2N0M0 | |
D07 | F | 71 | Ovary | Serous cystadenocarcinoma | III | T3N0M1 | |
D08 | F | 50 | Ovary | Serous cystadenocarcinoma | III | T3N0M1 | |
D09 | F | 53 | Ovary | Serous cystadenocarcinoma | III | T1N0M0 | |
D10 | F | 52 | Ovary | Serous cystadenocarcinoma | III | T1N0M0 | |
D11 | F | 58 | Ovary | Serous cystadenocarcinoma | III | T1N0M0 | |
D12 | F | 50 | Ovary | Serous cystadenocarcinoma | III | T1N0M0 | |
D13 | F | 59 | Ovary | Serous cystadenocarcinoma | III | T3N0M1 | |
E01 | F | 46 | Ovary | Serous cystadenocarcinoma | III | T2N0M0 | |
E02 | F | 40 | Ovary | Serous cystadenocarcinoma | III | T3N1M1 | |
E03 | F | 22 | Ovary | Mucinous cystadenocarcinoma | I | T1N0M0 | |
E04 | F | 38 | Ovary | Mucinous cystadenocarcinoma | I | T1N1M0 | |
E05 | F | 18 | Ovary | Mucinous cystadenocarcinoma | I | T1N0M0 | |
E06 | F | 20 | Ovary | Mucinous cystadenocarcinoma | I | T1N0M0 | |
E07 | F | 57 | Ovary | Mucinous cystadenocarcinoma | I | T1N0M0 | |
E08 | F | 76 | Ovary | Mucinous cystadenocarcinoma | I | T1N0M0 | |
E09 | F | 45 | Ovary | Mucinous cystadenocarcinoma | I | T3N0M1 | |
E10 | F | 56 | Ovary | Mucinous cystadenocarcinoma | I | T1N0M0 | |
E11 | F | 58 | Ovary | Serous cystadenocarcinoma | I~II | T2N0M0 | |
E12 | F | 44 | Ovary | Mucinous cystadenocarcinoma | I~II | T1N0M0 | |
E13 | F | 66 | Ovary | Mucinous cystadenocarcinoma | I~II | T1N0M0 | |
F01 | F | 65 | Ovary | Serous cystadenocarcinoma | I~II | T2N0M0 | |
F02 | F | 53 | Ovary | Mucinous cystadenocarcinoma | II | T1N0M0 | |
F03 | F | 52 | Ovary | Clear cell carcinoma | II | T1N0M0 | |
F04 | F | 50 | Ovary | Mucinous cystadenocarcinoma | II | T2N0M0 | |
F05 | F | 46 | Ovary | Mucinous cystadenocarcinoma | II | T1N0M0 | |
F06 | F | 43 | Ovary | Serous cystadenocarcinoma | III | T1N0M0 | |
F07 | F | 51 | Ovary | Mucinous cystadenocarcinoma | III | T2N0M0 | |
F08 | F | 44 | Ovary | Endometrioid adenocarcinoma | I | T2N0M0 | |
F09 | F | 82 | Ovary | Endometrioid adenocarcinoma | II | T1N0M0 | |
F10 | F | 51 | Ovary | Endometrioid adenocarcinoma | II | T1N0M0 | |
F11 | F | 44 | Ovary | Endometrioid adenocarcinoma | II | T1N0M0 | |
F12 | F | 43 | Ovary | Endometrioid adenocarcinoma | II | T3N0M0 | |
F13 | F | 62 | Ovary | Endometrioid adenocarcinoma | II | T1N0M0 | |
G01 | F | 59 | Ovary | Serous cystadenocarcinoma | II | T3N0M1 | |
G02 | F | 53 | Ovary | Endometrioid adenocarcinoma | II | T1N0M0 | |
G03 | F | 44 | Ovary | Endometrioid adenocarcinoma | II~III | T1N0M0 | |
G04 | F | 66 | Ovary | Serous cystadenocarcinoma | II~III | T1N0M0 | |
G05 | F | 42 | Ovary | Endometrioid adenocarcinoma | III | T2N0M0 | |
G06 | F | 51 | Ovary | Endometrioid adenocarcinoma | III | T1N0M0 | |
G07 | F | 48 | Ovary | Endometrioid adenocarcinoma | III | T1N0M0 | |
G08 | F | 43 | Ovary | Mucinous cystadenocarcinoma | III | T2N0M0 | |
G09 | F | 54 | Ovary | Endometrioid adenocarcinoma | III | T2N0M0 | |
G10 | F | 58 | Ovary | Endometrioid adenocarcinoma | III | T2N0M0 | |
G11 | F | 68 | Ovary | Endometrioid adenocarcinoma | III | T3N1M0 | |
G12 | F | 49 | Ovary | Endometrioid adenocarcinoma | III | T1N0M0 | |
H01 | F | 51 | Ovary | Endometrioid adenocarcinoma | III | T1N0M0 | |
H02 | F | 65 | Ovary | Endometrioid adenocarcinoma | III | T1N0M0 | |
H03 | F | 51 | Ovary | Serous cystadenocarcinoma | III | T1N0M0 | |
H04 | F | 71 | Ovary | Endometrioid adenocarcinoma | III | T3N0M1 | |
H05 | F | 58 | Ovary | Endometrioid adenocarcinoma | III | T3N0M1 | |
H06 | F | 44 | Ovary | Serous cystadenocarcinoma | III | T2N0M0 | |
H07 | F | 41 | Ovary | Endometrioid adenocarcinoma | III | T1N0M0 | |
H08 | F | 59 | Ovary | Endometrioid adenocarcinoma | III | T1N0M0 | |
H09 | F | 53 | Ovary | Endometrioid adenocarcinoma | III | T1N0M0 | |
H10 | F | 65 | Ovary | Endometrioid adenocarcinoma | III | T3N1M1 | |
H11 | F | 60 | Ovary | Endometrioid adenocarcinoma | III | T3N0M1 | |
H12 | F | 57 | Ovary | Endometrioid adenocarcinoma | III | T3N0M1 | |
null |
